OptiBiotix Health PLC Directorate Change (4549V)
December 04 2023 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 4549V
OptiBiotix Health PLC
04 December 2023
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Directorate change
OptiBiotix Health p lc (AI M: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skincare, a nnounces that Graham Myers has been appointed as
Finance Director of the Company as of 1 December 2023 .
Graham is a member of the Institute of Chartered Accountants in
England & Wales and has extensive financial and commercial
experience in a number of private and public companies, including
being a member of the Executive Committee at Croda International
Plc, where he worked for almost 30 years. Graham brings extensive
experience in optimising financial controls, managing budgets,
building profitable businesses and mergers & acquisitions.
Graham is currently Chair of Croda Pension Trustees Limited, the
sole trustee of Croda's GBP800m UK pension scheme.
Graham's appointment to this part-time role will see him work
closely with the OptiBiotix team to support the focus on driving
each business unit and the Group to profitability.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies, the following information is disclosed in respect of
Graham Lloyd Myers (aged 60):
Current Directorships Previous Directorships held in the
past five years
Croda Pension Trustees
Limited Bio Futures PI Limited
--------------------------------------
Croda Trustees Limited Cargill Bioindustrial BV (Previously
Croda Nederland BV)
--------------------------------------
Cowick Insurance Services Limited
--------------------------------------
Croda (Thailand) Co Ltd
--------------------------------------
Croda Cosmetics & Toiletries Limited
--------------------------------------
Croda Food Services Limited
--------------------------------------
Croda India Company Private Limited
--------------------------------------
Croda Investments Limited
--------------------------------------
Croda Investments No 2 Limited
--------------------------------------
Croda Investments No 3 Limited
--------------------------------------
Croda Overseas Holdings Limited
--------------------------------------
Croda Polymers International Limited
--------------------------------------
Croda World Traders Limited
--------------------------------------
Enza Biotech AB
--------------------------------------
Lanxess Urethanes UK Ltd
--------------------------------------
P. I. Bioscience Limited
--------------------------------------
Plant Impact Limited
--------------------------------------
PT. Croda Indonesia LLC
--------------------------------------
Uniqema Limited
--------------------------------------
Uniqema UK Limited
--------------------------------------
Graham Myers holds no ordinary shares, options or warrants over
ordinary shares in the Company.
There is no further information regarding Graham Myers required
to be disclosed under the AIM Rules.
Stephen OHara, CEO of OptiBiotix commented: " We are pleased to
confirm the appointment of Graham Myers as Finance Director. The
appointment reflects the progress we have made in 2023 after a
difficult 2022 and the Board's focus on controlling costs and
building revenues to create a profitable international business
with well-known global brands".
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
the UK Market Abuse Regulation and the Directors of the Company are
responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Joint Broker) Tel: 020 7220 9797
Duncan Vasey/ Lucy Williams
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEFLFBXLLEFBF
(END) Dow Jones Newswires
December 04, 2023 02:00 ET (07:00 GMT)
OptiBiotix Health (AQSE:OPTI.GB)
Historical Stock Chart
From Oct 2024 to Nov 2024
OptiBiotix Health (AQSE:OPTI.GB)
Historical Stock Chart
From Nov 2023 to Nov 2024
